Get the Stockscreener App
0.6426
1.83%
-0.012
Atossa Therapeutics Inc stock is traded at $0.6426, with a volume of 496.77K.
It is down -1.83% in the last 24 hours and down -6.07% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.6546
Open:
$0.66
24h Volume:
496.77K
Relative Volume:
0.45
Market Cap:
$82.51M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-2.9209
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
+4.49%
1M Performance:
-6.07%
6M Performance:
-27.50%
1Y Performance:
-31.56%
1-Day Range:
$0.63
$0.66
1-Week Range:
$0.5801
$0.661
52-Week Range:
$0.551
$1.29
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.6388 | 84.56M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.40 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.46 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.41 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.26 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - Nasdaq
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - Sahm
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Is Atossa Therapeutics Inc. (YAG2) stock supported by strong fundamentalsMarket Sentiment Report & Real-Time Volume Spike Alerts - Улправда
Bearish Setup: Will Atossa Therapeutics Inc. stock maintain growth storyJuly 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study By Investing.com - Investing.com India
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for - GuruFocus
Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial - TipRanks
FDA clears Atossa Therapeutics to begin (Z)-endoxifen study - Investing.com
Atossa Therapeutics Receives FDA Approval for Metastatic Breast Cancer Study - TradingView — Track All Markets
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer – Company AnnouncementFT.com - Financial Times
Reviewing Atossa Genetics (NASDAQ:ATOS) and Autonomix Medical (NASDAQ:AMIX) - Defense World
Seattle InnoDiagrid emerges from stealth I Atossa troubles - The Business Journals
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Increase in Short Interest - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving Average – Should You Sell? - Defense World
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Below 200 Day Moving AverageShould You Sell? - MarketBeat
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - norwichbulletin.com
Atossa Genetics (NASDAQ:ATOS) & IDEXX Laboratories (NASDAQ:IDXX) Head-To-Head Survey - Defense World
Will Atossa Therapeutics Inc. stock outperform international peersChart Signals & Community Consensus Trade Alerts - Улправда
Earnings Report: Is Atossa Therapeutics Inc. stock a buy before product launchesTake Profit & Smart Money Movement Tracker - Улправда
Atossa Therapeutics Earnings Notes - Trefis
Will Atossa Therapeutics Inc. stock maintain growth storyBond Market & Free AI Powered Buy and Sell Recommendations - DonanımHaber
Will Atossa Therapeutics Inc. stock maintain momentum in 2025Quarterly Earnings Report & Technical Pattern Based Signals - Улправда
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category - BioSpace
Atossa Therapeutics Wins R&D Excellence Award for Precision Endocrine Therapy Innovation - Clinical Trials Arena
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.30%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):